NASDAQ$RLAY
Relay Therapeutics Inc. · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Relay Therapeutics reported financial results for the second quarter of 2024 and provided corporate highlights.
Relay Therapeutics reported second quarter 2024 financial results, highlighting progress in clinical programs and expansion of the RLY-2608 development program. The company announced new pre-clinical programs and anticipates multiple data readouts later in the year. Cash reserves are expected to fund operations into the second half of 2026.
- Announced 3 new programs, including genetic disease programs in vascular malformations, Fabry disease, as well as precision oncology program with NRAS-specific inhibitor
- Initiated global clinical trial collaboration with Pfizer for combination development of RLY-2608 + fulvestrant + atirmociclib in PI3Kα-mutated HR+/HER2- metastatic breast cancer, with clinical start planned by end of 2024
- Continued to enroll patients in the RLY-2608 (ReDiscover study)
- Approximately $688 million in cash, cash equivalents and investments at end of Q2 2024, expected to fund operations into second half of 2026
Headline financials
Revenue & EPS history
Relay Therapeutics · Revenue · Quarterly
$10M
Revenue by segment
Relay Therapeutics · $25.2M total across 1 segment · Q3 2023
- License and Other Revenue$25.2M—100.0%
Forward guidance
Relay Therapeutics anticipates several milestones in the near future.
Tailwinds
- RLY-2608 + fulvestrant data update in the fourth quarter of 2024
- RLY-2608 + fulvestrant + ribociclib initial safety data in the fourth quarter of 2024
- RLY-2608 + fulvestrant + atirmociclib clinical trial initiation by the end of 2024
- RLY-2608 + fulvestrant potential Phase 3 trial initiation in 2025
- Lirafugratinib: tumor agnostic data and regulatory update in the second half of 2024
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+0.2%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-0.5%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+11.7%
Q4 2025
Best reaction
-19.5%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.7% | -2.5% | +11.1% | |
| Q4 2025 | +11.7% | +10.8% | +4.8% | |
| Q3 2025 | -7.4% | -5.5% | +17.6% | |
| Q1 2025 | -4.8% | -9.6% | -2.4% | |
| Q4 2024 | -13.3% | -14.9% | -27.5% | |
| Q3 2024 | +3.2% | +3.5% | -22.5% | |
| Q2 2024 | -6.8% | -5.6% | -8.6% | |
| Q1 2024 | +5.7% | +1.2% | -3.8% | |
| Q4 2023 | -4.6% | -1.8% | -25.7% | |
| Q3 2023 | +10.1% | +19.3% | +27.4% | |
| Q2 2023 | +7.8% | +3.5% | -3.2% | |
| Q1 2023 | +0.5% | -5.3% | +2.3% | |
| Q4 2022 | -3.6% | -8.8% | -13.5% | |
| Q3 2022 | -4.3% | -6.8% | -12.4% | |
| Q2 2022 | +3.8% | -1.6% | +31.7% | |
| Q1 2022 | -19.5% | -33.5% | -31.6% | |
| Q4 2021 | +11.5% | +17.4% | +40.1% | |
| Q3 2021 | +1.7% | +0.6% | -19.6% | |
| Q2 2021 | +1.0% | +0.2% | -1.7% | |
| Q1 2021 | +5.7% | +8.5% | +23.9% | |
| Q4 2020 | -2.3% | +2.0% | -13.5% | |
| Q3 2020 | +0.5% | +13.5% | +5.7% | |
| Q2 2020 | +8.0% | +5.3% | +8.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro